From: Effectiveness and safety of moxibustion for primary insomnia: a systematic review and meta-analysis
a. Moxibustion vs. Western medications | ||||||
Included trials | Eligibility criteria | Interventions and treatment duration | Sample and characteristics (male female, age, disease duration) | Outcome Criteria (effective rate Criteria) | ||
 |  | Trial | Control | Trial | Control | |
Wu 2014 [59] | CD&TETCMD&S | Moxibustion Duration:30d | Estazolam Duration:30d | 91; AGE: 20-75; Disease duration:3Â m-30y | 91; AGE: 20-75; Disease duration:3Â m-30y; | Unclear |
Wong 2014 [62] | CCMD-3 | Moxibustion Duration:20d | Estazolam Duration:20d | 40 (M: 18, F: 22); AGE: 18-63 (mean: 38); Disease duration: 1.5Â m-4y | 40 (M: 16; F: 24); AGE: 18-66 (mean: 39); Disease duration:1.2Â m-6y | GCTNPCM |
Yu 2012 [60] | -CCMD-3 -ICD10 | Moxibustion Duration:21d | Estazolam Duration: 14 d | 30; AGE: 13-65; Disease duration: 1Â m-8 y | 30; AGE: 13-65; Disease duration:1Â m-8y; | GCTNPCM |
Ju 2009 [54] | Sleep efficiency computation | Moxibustion Duration:10d | Estazolam Duration: 10 d | 40 (M: 18, F: 22); AGE: 25-75; Disease duration: 0.5y-5 y | 35 (M: 14Â F: 21); AGE: 25-75; Disease duration:0.5y-5y | Sleep efficiency computation |
Yuan 2007 [61] | -CCMD-3 -ICD10 | Moxibustion Duration:20d | -Diazepam -Oryzanol --VB1 Duration: 20 d | 40; AGE 14-65; Disease duration: 1Â m-10 y; | 40; AGE 14-65; Disease duration:1Â m-10 y; | GCTNPCM |
b. Moxibustion vs. oral Chinese medicine | ||||||
Included trials | Eligibility criteria | Interventions and treatment duration | Sample and characteristics (male female, age, disease duration) | Outcome Criteria (effective rate Criteria) | ||
 |  | Trial | Control | Trial | Control | |
Jiao 2015 [65] | -CCMD-3 -CDT&ETCMD&S | -Moxibustion -SanhuangAnshen Decoction Duration: 30d | SanhuangAnshen Decoction Duration: 30d | 80 (M: 37, F: 43); AGE: (mean: 67.8); Disease duration: -; | 79 (M: -, F: -); AGE: (mean: 65.1); Disease duration: -; | CDT&ETCMD&S |
Liu 2015 [66] | -CCMD-3 -GCTNPCM | Grain-moxibustion Duration: 14 d | Renshenguipi pill Duration: 14 d | 38; AGE: 18-70; Disease duration: -; | 38; AGE: 18-70; Disease duration: -; | GCTNPCM |
Zhang 2014 [68] | -CCMD-3 | -Moxibustion -Huatanjieyu decoction Duration: 10 d | Huatanjieyu decoction Duration: 7 d | 59; AGE: 34-65; Disease duration: -; | 59; AGE: 34-65; Disease duration: -; | Unclear |
He 2014 [63] | -ICD-10- -GCTNPCM | -Moxibustion -Tianwangbuxin decoction Duration: 32 d | Tianwangbuxin decoction Duration: 28 d | 30 (M: 12, F: 18); AGE:30-60 (mean:45.3 ± 4. 4); Disease duration: -; | 30 (M: 13, F: 17); AGE:31-60 (mean:46.2 ± 5.1); Disease duration: -; | GCTNPCM |
Wu 2010 [67] | -CCMD-3 -CDT&ETCMD&S | -Heat-sensitive Moxibustion –AnshenBunao decoction Duration: 22 d | AnshenBunao decoction Duration: 22 d | 30 (M: 13, F: 17); AGE:33-74 (mean:46.8); Disease duration: 1 w-2.7 y | 30 (M: 11, F: 19); AGE:35-75 (mean:45.7); Disease duration: 1w-2.5 y | GCTNPCM |
Hu 2007 [64] | PSQI | Moxibustion Duration: 30 d | AnshenBunao Ye Duration: 30 d | 30 (M: 12, F: 18); AGE: 19-65; Disease duration: 24 d-16 y | 30 (M: 14, F: 16); AGE: 18-67; Disease duration: 20 d-14 y | PSQI |
c. Moxibustion vs. other TCM therapies | ||||||
Included trials | Eligibility criteria | Interventions and treatment duration | Sample and characteristics (male female, age, disease duration) | Outcome Criteria (effective rate criteria) | ||
 |  | Trial | Control | Trial | Control | |
Xie 2015 [77] | CCMD-3 | -Moxibustion -Head-acupoint massage Duration: 28 d | Head-acupoint massage Duration: 28 d | 30 (M: 17, F: 13); AGE: (mean: 43.3 ± 13.8 y); Disease duration: (mean: 11.5 ± 5.3 m); | 30 (M: 14, F: 16); AGE: (mean: 42.7 ± 12.4 y); Disease duration: (mean: 10.8 ± 4.7 m); | GCTNPCM |
Wang 2014 [76] | Unclear | -Moxibustion -Point-application Duration:15 d | Point-application Duration:15 d | 18 (M: 10, F: 8); AGE:39-65y (mean:45.2 y); Disease duration: - | 18 (M: 11, F: 7); AGE:41-69y (mean:48.1 y); Disease duration: - | Unclear |
Xu 2014 [78] | CD&TETCMD&S | -Heat-sensitive Moxibustion -Head-needle acupuncture Duration:24 d | Head-needle acupuncture Duration:24 d | 58 (M: -, F: -); AGE: 18-70 y; Disease duration: 12Â m-60Â m | 54 (M: -,F: -); AGE: 18-70 y; Disease duration: 12Â m-60Â m | sleep efficiency by international standard |
Shu 2014 [75] | GCTNPCM | -Moxibustion -Head-acupoint massage Duration:15 d | Head-acupoint massage Duration: 15 d | 9 (M: 0, F: 9); AGE: 30-56; Disease duration: 2Â m-7Â m | 9 (M: 0, F: 9); AGE: 30-56; Disease duration: 2Â m-7Â m | GCTNPCM |
Ma 2014 [73] | CCMD-3 | -Moxibustion -Auricular-plaster therapy Duration:47 d | Auricular-plaster therapy Duration:47 d | 99 (M: 38, F: 61); AGE: 20-64 y (mean: 38 ± 13 y); Disease duration: 0.5 y-20y (mean: 7.48 ± 4.57 y) | 96 (M: 33, F: 63); AGE: 21-62 y (mean: 37 ± 12 y); Disease duration: 0.5 y-20 y (mean: 7.13 ± 4.92 y) | unclear |
Li 2014 [70] | ICD-10 | -Moxibustion -Acupuncture Duration:21 d | -Acupuncture Duration:21 d | 35 (M: 12, F: 23); AGE: 20-60 y (mean: 45 ± 3. 5 y); Disease duration: 1 m-18 m (mean: 5.5 ± 4.2 m) | 35 (M: 8, F: 27); AGE: 25-60 (mean: 48 ± 4. 9 y); Disease duration: 1 m-18 m (mean: 5.6 ± 0.4 m) | GCTNPCM |
Quan 2012 [74] | CCMD-2-R | -Moxibustion -Acupuncture Duration:43 d | Acupuncture Duration:43 d | 36 (M: 15, F: 21); AGE: 19-67 y (mean:38.9 y); Disease duration: 6Â m-9 y (mean: 5.3 y); | 36 (M: 17, F: 19); AGE: 20-68 y (mean:40.6 y); Disease duration: 5Â m-10 y (mean: 5 y); | GCTNPCM |
Ao 2011 [69] | CCMD-3 | -Moxibustion -Acupuncture Duration:32-33 d | Acupuncture Duration:32-33d | 34 (M: 13, F: 21); AGE: (mean:40.54 ± 11.27); Disease duration: (mean: 9.7 ± 2.45 m); | 33 (M: 14, F: 19); AGE: (mean:39.67 ± 11.93); Disease duration: (mean: 8.47 ± 1.69 m); | Sleep efficiency by international standard |
Li 2011 [5] | CCMD-3 | -Moxibustion -Acupuncture Duration:28 d | Acupuncture Duration:28 d | 100 (M: 46, F: 54); AGE: (mean: 35.58 ± 9.87); Disease duration: (mean: 21.59 ± 7.87 m); | 98 (M: 45, F: 53); AGE: (mean: 36.67 ± 10.93); Disease duration:(mean: 22.76 ± 8.39 m); | GCTNPCM |
Chen 2010 [71] | -CCMD-3 -ICD -10 | -Moxibustion -Auricular-plaster therapy Duration:22-23 d | Auricular-plaster therapy Duration:22-23d | 37 (M: -,F: -); AGE:18-72 (mean:48); Disease duration: 2Â m-7y | 26 (M: -,F: -); AGE:18-72 (mean:48); Disease duration: 2Â m-7 y | Unclear |
Li 2010 [72] | -CCMD-2-R -CD&TETCMD&S | -Thunder-fire moxibustion -Acupuncture Duration:10-30 d | Acupuncture Duration:10-30d | 35 (M: 15, F: 20); AGE: (mean: 35.6); Disease duration: (mean: 3.3 y); | 35 (M: 16, F: 19); AGE: (mean: 33.6); Disease duration: (mean: 3.6 y); | GCTNPCM |